Mario Negri Institute for Pharmacological Research
184
21
35
89
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
16.8%
31 terminated/withdrawn out of 184 trials
74.2%
-12.3% vs industry average
23%
42 trials in Phase 3/4
8%
7 of 89 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (184)
CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
Role: collaborator
New Analytic Tools for aHUS and C3G Diagnosis
Role: lead
A Possible Founding PKD2 Mutation Associated With Variable Phenotypes of ADPKD in Bergamo Province
Role: lead
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
Role: lead
An Outcome Analysis of Primary Membranous Nephropathy
Role: lead
Autoreactive B Cells in Membranous Nephropathy
Role: lead
Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy
Role: lead
Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib
Role: lead
Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.
Role: lead
Omics of Rituximab-resistance
Role: lead
Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome
Role: lead
AVF-MONITOR POC Proof-of-concept Study
Role: lead
RESOLving INflammation Through Diet for Health (RESOLVIN)
Role: lead
Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer
Role: lead
Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen
Role: lead
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
Role: lead
Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression
Role: lead
MuLtidimensional School-based and Family interVentions to Promote hEalthy and Sustainable LifestYle for the Childhood
Role: lead
Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy
Role: lead
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS
Role: lead